静脉注射对比剂后急性肾损伤的风险
该单中心回顾性队列分析纳入2009至2014年5年间17,934例在大型城市学术急诊科接受增强、平扫或无CT的急诊就诊患者,比较静脉对比剂给药与急性肾损伤及临床结局的关系。主要结局急性肾损伤发生率在各组间相似,对比剂给药与急性肾损伤无独立关联(对比剂肾病标准OR=0.96,95%CI 0.85–1.08;AKIN/KDIGO标准OR=1.00,95%CI 0.87–1.16),各亚组及倾向性匹配后结果一致。对比剂给药与6个月新发慢性肾脏病、透析或肾移植也无关联。临床医生对肾功能下降者更少处方对比剂,若给予对比剂则更可能处方静脉液体。
要点
- 在急诊CT患者中,静脉对比剂给药与急性肾损伤发生率升高无独立关联(对比剂肾病标准OR=0.96,95%CI 0.85–1.08)。
- 按AKIN/KDIGO标准,对比剂给药与急性肾损伤同样无关联(OR=1.00,95%CI 0.87–1.16)。
- 无论基线肾功能如何、直接比较或倾向性匹配后,各亚组分析均显示对比剂与急性肾损伤无关联。
- 对比剂给药与6个月新发慢性肾脏病、透析或肾移植无关联。
- 临床医生对肾功能下降者更少处方对比剂,给予对比剂时更可能处方静脉液体。
适用人群与场景
- 2009至2014年5年间在大型城市学术急诊科(年均就诊量62,179例次)接受增强CT、平扫CT或无CT的17,934例急诊就诊患者。
- 亚组分析涵盖不同基线肾功能状态的患者。
诊断标准与关键阈值
- 急性肾损伤采用对比剂肾病标准及急性肾损伤网络/肾脏病改善全球结局(AKIN/KDIGO)标准判定。
研究设计与关键结果
- 研究类型为单中心回顾性队列分析,纳入17,934例急诊就诊患者,比较CT增强与否,主要终点为急性肾损伤发生率。
- 急性肾损伤发生率在各组间相似;对比剂给药与急性肾损伤无独立关联:对比剂肾病标准OR=0.96(95%CI 0.85–1.08),AKIN/KDIGO标准OR=1.00(95%CI 0.87–1.16)。
- 各亚组分析(无论基线肾功能)及倾向性匹配后结果一致。
- 对比剂给药与6个月新发慢性肾脏病、透析或肾移植无关联。
- 临床医生对肾功能下降者更少处方对比剂,给予对比剂时更可能处方静脉液体。
证据类型、等级与局限
- 证据类型:单中心回顾性队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,静脉对比剂与急性肾损伤发生率升高无关联。
- 临床医生对肾功能下降者更少处方对比剂,给予对比剂时更可能处方静脉液体。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: The study objective was to determine whether intravenous contrast administration for computed tomography (CT) is independently associated with increased risk for acute kidney injury and adverse clinical outcomes.
METHODS: This single-center retrospective cohort analysis was performed in a large, urban, academic emergency department with an average census of 62,179 visits per year; 17,934 ED visits for patients who underwent contrast-enhanced, unenhanced, or no CT during a 5-year period (2009 to 2014) were included. The intervention was CT scan with or without intravenous contrast administration. The primary outcome was incidence of acute kidney injury. Secondary outcomes included new chronic kidney disease, dialysis, and renal transplantation at 6 months. Logistic regression modeling and between-groups odds ratios with and without propensity-score matching were used to test for an independent association between contrast administration and primary and secondary outcomes. Treatment decisions, including administration of contrast and intravenous fluids, were examined.
RESULTS: Rates of acute kidney injury were similar among all groups. Contrast administration was not associated with increased incidence of acute kidney injury (contrast-induced nephropathy criteria odds ratio=0.96, 95% confidence interval 0.85 to 1.08; and Acute Kidney Injury Network/Kidney Disease Improving Global Outcomes criteria odds ratio=1.00, 95% confidence interval 0.87 to 1.16). This was true in all subgroup analyses regardless of baseline renal function and whether comparisons were made directly or after propensity matching. Contrast administration was not associated with increased incidence of chronic kidney disease, dialysis, or renal transplant at 6 months. Clinicians were less likely to prescribe contrast to patients with decreased renal function and more likely to prescribe intravenous fluids if contrast was administered.
CONCLUSION: In the largest well-controlled study of acute kidney injury following contrast administration in the ED to date, intravenous contrast was not associated with an increased frequency of acute kidney injury.
参考来源
- Hinson JS, Ehmann MR, Fine DM, et al. Risk of Acute Kidney Injury After Intravenous Contrast Media Administration. Ann Emerg Med. 2017. PMID: 28131489. doi:10.1016/j.annemergmed.2016.11.021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。